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Abstract 
Introduction: The objective of this study was to investigate the possible relation between serum adiponectin and osteopontin levels as 
metabolic risk markers among women with different polycystic ovary syndrome (PCOS) phenotypes.
Material and methods: In a University Hospital setting PCOS patients diagnosed according to Rotterdam Consensus Conference criteria 
with body mass index (BMI) between 18 and 35 were recruited.
Results: Overall, 57 PCOS patients and 57 age- and BMI-matched healthy controls were included in the study. Luteinising hormone (LH) 
to follicle-stimulating hormone FSH ratio (LH/FSH), free androgen index (FAI), and dehydroepiandrosterone sulphate (DHEAS-S) was 
found to be significantly higher in women with PCOS. There was significant interaction between PCOS status and obesity for serum 
adiponectin levels. Although mean adiponectin and osteopontin levels were similar among cases and controls, a further two-way ANOVA 
comparison within lean and obese subgroups revealed adiponectin to be significantly lower in lean PCOS women than in lean controls. 
LH/FSH ratio and adiponectin levels were all found to differ between lean counterparts; however, they did not show any correlation 
with metabolic markers [cholesterol, homeostatic model assessment (HOMA) or C-reactive protein (CRP) levels] in overall lean women 
or in the lean PCOS subgroup.
Conclusion: Serum adiponectin levels in lean PCOS women were significantly lower than those in lean controls. On the other hand, mean 
adiponectin and osteopontin levels were similar in PCOS cases and controls overall. (Endokrynol Pol 2020; 71 (6): 497–503)
Key words: adiponectin; osteopontin; polycystic ovary syndrome
Endokrynologia Polska
DOI: 10.5603/EP.a2020.0074
Volume/Tom 71; Number/Numer 6/2020
ISSN 0423–104X
Introduction
Polycystic ovary syndrome (PCOS) is the most common 
endocrine disorder, which is characterised by ovula-
tory abnormalities, hyperandrogenism, and insulin 
resistance (IR) [1]. According to the Rotterdam criteria, 
diagnosis of PCOS requires at least two of the follow-
ing three findings: hyperandrogenism (HA), ovulatory 
dysfunction (OD), and polycystic ovarian morphol-
ogy (PCO) [1]. Therefore, the possible combination 
of these factors results in four different phenotypes 
(HA+OD, HA+PCO, OD+PCO, and HA+OD+PCO) 
all of which are defined as the same disease. Polycystic 
ovary syndrome represents a heterogeneous genetic 
condition of reproductive age with a relatively high 
prevalence of up to 15% of all women [2]. The exact 
underlying disease remains still unclear; however, it 
has been well established that it is not only often as-
sociated with ovulatory dysfunction, but also a crucial 
inflammatory-based metabolic course interrelated with 
IR plays a crucial role for this syndrome. In line with 
this fact, IR is detected in 40–70% of women diagnosed 
with PCOS [3]. 
Many putative molecules have been proposed to be 
involved in PCOS pathogenesis and related metabolic 
disturbances. Hepatokines, adipokines, myokines, and 
cytokines that have been reported to be associated with 
PCOS include, but are not limited to, Fetuin-A, lipo-
calin-2, adropin, leptin, and irisin [4–7]. It has long been 
known that women with PCOS appear to have a high 
risk for central obesity [8]. It was previously established 
that obesity causes hormonal, metabolic, and inflam-
matory alterations by means of effecting cytokine, 
adipokine, and inflammatory mediator secretions [9, 
10]. Although obesity accompanies insulin resistance in 
many cases, non-obese PCOS patients can also present 
with insulin resistance that can be regarded to be related 
with inflammation [11]. There is still limited evidence 
on whether metabolic changes are related to the disease 
itself or only the results of obesity. 
Adipokines are cytokines that are produced mainly 
by adipose tissue itself and play a key role in insulin 
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different PCOS phenotypes may differ. More data are 
needed to define the long-term prognosis and moni-
tor complications associated with these alterations in 
different PCOS phenotypes. Therefore, investigating 
the clinical usefulness of putative markers holds im-
portance not only for dissecting the pathophysiology of 
the disease, but also for understanding the association 
of these markers with further complications. Because 
adiponectin and osteopontin are reported, as putative 
markers, to play a role in the pathogenesis and clinical 
manifestation of PCOS, it would be important to evalu-
ate them to define both their individual roles and their 
association with each other. To our knowledge, there has 
been no report to analyse the association of both in the 
same population according to body mass index (BMI). 
Therefore, this study aimed to investigate the possible 
relation between serum osteopontin and adiponectin 
levels as metabolic risk markers among women with dif-
ferent PCOS phenotypes. We also intended to evaluate 
the correlation of metabolic profiles in distinct PCOS 
phenotypes with respect to metabolic disturbances.
Material and methods
Study population
Female patients between the ages of 18 and 45 years, who were 
diagnosed according to Rotterdam Consensus Conference criteria, 
were included in the study. The control group consisted of age-
matched healthy women who attended the gynaecology clinic 
for contraception or other gynaecological issues. Matching was 
achieved in lean and obese counterparts by recruiting one control 
who was within five years of age of the patient. This study was 
conducted in a University Hospital setting. Institutional Ethical 
Board approval was obtained for the study, and all participants 
gave consent. 
Inclusion criteria were defined as follows: 18–45 years old PCOS 
patients diagnosed according to Rotterdam Consensus Conference 
criteria, exclusion of other endocrinopathies, having spontaneous 
menarche and normal sexual development, and BMI between 18 
and 35. Exclusion criteria were defined as follows: taking medica-
tions that can affect sex steroid levels and menstruation, previous 
diagnosis of diabetes mellitus and taking antidiabetic drugs, 
chronic renal or liver disease, haematological disorders, history 
of any oncological disease, and chemo/radiotherapy. Women in-
cidentally diagnosed with elevated liver tests were also excluded 
because their condition might have affect serum hormone levels 
and the exact cause of this elevation was not established at the time 
of serum collection and analysis. According to the inclusion and 
exclusion criteria, 57 women were included in the PCOS group for 
comparison with age- and BMI-matched healthy controls. Institu-
tional Ethical Board approval was obtained for the study, and all 
participants gave consent.
Evaluation and measurements
Menstrual and gynaecological history was assessed by a gynae-
cologist using a standardised investigation form. Irregular cycles 
were defined as follows: oligomenorrhoea, cycle length between 36 
and 180 days; or amenorrhoea, absence of any menstrual bleeding 
for more than 180 days. Either Modified Ferriman-Gallway (F-G) 
scores (evaluated at least two months after any kind of epilation) of 
more than 8 or the presence of acne and/or alopecia was regarded 
as clinical HA. Biochemical hyperandrogenism was defined when 
sensitivity as well as inflammation. It has been docu-
mented that adiponectin is actively involved in glucose 
homeostasis and insulin metabolism [12]. Furthermore, 
adiponectin is regarded as an insulin sensitising agent 
because a low level of adiponectin was found to be as-
sociated with IR and increased risk of type 2 diabetes 
mellitus [13]. Interestingly, adiponectin has also been re-
ported to exert anti-inflammatory and antiatherogenic 
properties [14]. The effects of adiponectin are mediated 
mainly via two receptors, AdipoR1 and AdipoR2, which 
are also expressed in female reproductive tissue, such 
as ovary, placenta, endometrium, and oviduct [15, 16]. 
It has been suggested that hypoadiponectinaemia may 
also play a role in the pathogenesis of PCOS in relation 
with hyperandrogenaemia, obesity, and IR [16, 17]. 
Results regarding the role of adiponectin in PCOS 
have been inconsistent, and it is still unresolved 
whether adiponectin alteration is intrinsic to PCOS 
pathophysiology or secondary to PCOS-associated 
obesity and other metabolic alterations [18]. In addition, 
there is strong evidence that IR is related with adipose 
tissue involving the secretion of inflammatory cytokines 
[19]. Immune modulator molecules may play a role in 
inflammatory pathways in several ways: Firstly, they 
can promote cell recruitment to inflammatory sites; 
secondly, they may effect cell activation and cytokine 
secretion; and lastly, they can regulate cell cycle and 
apoptosis of several cell types. Osteopontin (OPN) 
is a multi-functional extracellular matrix-associated 
phosphoprotein that plays a remarkable role in cell 
macrophage activation, chemotaxis, vascularisation, 
inflammation, matrix remodelling, and inhibition of 
apoptotic activities [19, 20]. It has been proposed that 
osteopontin plays an important role in macrophage 
recruitment to inflammation in adipose tissue and 
contributes to chronic low-grade inflammation [20]. In 
relation to macrophage infiltration and inflammation, 
OPN is also demonstrated to associate in the pathogen-
esis of atherosclerotic process, insulin resistance, and 
malignant disorders [19]. Recently only a few studies 
have indicated that increased osteopontin levels may be 
associated with PCOS in selected populations [14, 21].
To date, many molecular markers have been in-
vestigated in PCOS patients; however, no exact cause 
and effect could be documented except significant 
associations. The main reason for this is the fact that 
the pathogenesis of PCOS is complex, phenotypes are 
heterogenous, and the disease is not limited to obese 
women. Heterogeneity is an inherent feature of PCOS 
from its aetiology to its presentation [4]. PCOS presenta-
tion is not homogenous, and in terms of manifestation, 
patients can also be grouped in to different types such 
as metabolic PCOS or reproductive PCOS [22]. Ozga 
et al. argued that metabolic and androgenic status of 
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total testosterone, free testosterone, dehydroepiandrosterone 
sulphate and/or androstenedione exceeded laboratory limits or 
when calculated free androgen index (FAI) was greater than 5. 
Anthropometric measurements of the women were noted, and the 
BMI and waist-to-hip ratio (WHR) were calculated. Blood samples 
were collected during the early follicular phase after overnight 
fasting. Follicle-stimulating hormone (FSH), luteinising hormone 
(LH), oestradiol (E2), progesterone (P), 17-hydroxyprogesterone 
(17-OHP), prolactin, sex hormone-binding globulin (SHBG), total 
testosterone (T), dehydroepiandrosterone sulphate (DHEAS), total 
cholesterol, low-density lipoprotein (LDL), high-density lipoprotein 
(HDL), very low-density lipoprotein (VLDL), triglyceride, complete 
blood count, renal and liver function markers, and total urine 
analysis were assayed. Free androgen index (FAI) was calculated 
according to the defined formula: 
(T × 100)/SHBG
Insulin resistance was also calculated using the following formula:
(fasting glucose [mg/dL] × fasting insulin [uIU])/405 
and recorded as HOMA-IR. Serum adiponectin and osteopontin 
levels were determined by sandwich ELISA using secondary 
rabbit antibodies as described by the manufacturer (B-Bridge 
International, Inc., USA). Total testosterone, SHBG, DHEAS, TSH, 
and prolactin concentrations were measured by electrochemilumi-
nescent immunoassay with a inter- and intra-assay coefficient of 
variation (CV) of < 5%. The serum levels of androstenedione and 
free testosterone were analysed using the radioactive immunoassay 
method. Total cholesterol, HDL, and triglycerides were analysed 
using an enzymatic colorimetric assay. Analyses were performed on 
Cobas e602 apparatus (Roche Diagnostics GmbH, Manheim, Ger-
many). Pelvic or transvaginal sonographic (when suitable) evalu-
ation was performed on the same day of blood sample collection. 
Statistical analysis
The sample size was calculated in order to achieve a power of 95% 
with an alpha error of 0.05. The minimum sample size in each 
groups of lean and obese women was calculated by G-power to be 
at least 28 for serum osteopontin comparison with an effect size of 
0.985 according to reported values of 69.12 ± 31.59 ng/mL vs. 42.66 
± 21.28 ng/mL by Saklamaz et al. [14]. In total 28 and 29 women 
were included to these groups that added up to 57 cases and 57 
controls with a one-to-one case-control ratio. This sample size was 
also suitable to achieve the same power for serum adiponectin 
comparisons with an effect size of 3.385 according to the results 
of Baldani et al. [18]. 
Statistical tests were performed by PSPP 1.0.1 and R software us-
ing EasyR plugin. Numerical variables were presented as mean ± 
standard deviation (SD). Categorical parameters were presented 
along with their percentages. Normality tests were performed by 
distribution analysis and Kolmogorov-Smirnov test. Parametric 
Student’s t-test was used when normality was reached; otherwise, 
Mann-Whitney U test was utilised. p < .05 was considered as 
statistically significant. 
Results
Overall, 57 PCOS patients and 57 age- and BMI-matched 
healthy controls were included to the study. Patients 
with a BMI between 18 and 35 were selected for analysis 
in order to eliminate outlier values. Patients and cases 
were further divided into lean and obese groups ac-
cording to BMI below or above of 25. Altogether, there 
were total 28, 29, 28, and 29 lean control, obese control, 
lean PCOS, and obese PCOS participants, respectively. 
Mean age, BMI, and WHR among control and PCOS 
groups were similar. The baseline characteristics of 
the two main groups along with four subgroups are 
presented in Table 1. 
The laboratory parameters of the PCOS and the 
controls were investigated and are presented in Table 2, 
including all subgroups. Among the investigated labo-
ratory parameters LF/FSH ration, FAI, and dehydroepi-
androsterone sulphate (DHEAS-S) were found to be 
significantly different between the PCOS and control 
groups. A post-hoc analysis among lean and obese 
counterparts, however, revealed that FAI differed only 
between obese control and obese PCOS women but not 
in lean cases and controls. The only parameter that sig-
nificantly differed between lean controls and lean PCOS 
women appeared to be the LH/FSH ratio. On the other 
hand, LH/FSH and FAI were significantly different 
between obese control and obese PCOS cases. DHEA-
S was not found to significantly differ between lean 
control and lean PCOS or between obese control and 
obese PCOS women. For the PCOS cases, being lean 
or obese significantly affected total cholesterol, LDL, 
HDL, and C-reactive protein (CRP) levels.
Mean adiponectin levels were investigated by 
two-way ANOVA. This analysis revealed slightly signifi-












(n = 28) 
X ± SD
Obese Control 
(n = 29) 
X ± SD
Lean PCOS 
(n = 28) 
X ± SD
Obese PCOS 
(n = 29) 
X ± SD
Age [yrs] 27.2 ± 8.3 25.0 ± 5.8 0.1 22.4 ± 5.0 31.8 ± 8.3 22.6 ± 5.0 27.2 ± 5.7
BMI [kg/m2] 25.0 ± 5.1 24.6 ± 4.5 0.7 20.9 ± 1.9 28.8 ± 4.2 20.6 ± 1.3 28.4 ± 3.0
WHR 0.76 ± 0.06 0.78 ± 0.07 0.3 0.74 ± 0.05 0.79 ± 0.05 0.74 ± 0.05 0.81 ± 0.06
Antral follicle count 4.4 ± 2.9 16.7 ± 4.4 < 0.001 4.4 ± 2.8 4.4 ± 2.9 17.0 ± 4.7 16.5 ± 4.1
Ovarian volume [cm3] 8.7 ± 2.3 11.9 ± 2.9 < 0.001 8.6 ± 2.0 8.8 ± 2.5 12.4 ± 3.0 11.6 ± 3.0
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cant interaction between PCOS status and obesity for 
serum adiponectin levels, F(1, 110) = 4.567, p = 0.035, 
partial eta squared = .040. Therefore, we further calcu-
lated the simple main effects. Because this interaction 
seems to be ordinal we also measured the main effect, 
which was found to be insignificant for adiponectin 
between PCOS and controls, F(1, 110) = 3.021, p = .085, 
partial eta squared = .027. For the lean women the 
mean adiponectin level was 4.2 ng/mL (95% CI, 1.1 to 
7.2) lower in PCOS cases than controls, F(1, 110) = 7.38, 
p = .008, partial eta squared = .063). However, the 
simple main effect of PCOS status on adiponectin levels 
for those being obese was not statistically significant, 
F(1, 110) = .081, p = .776, partial eta squared = .001). 
On the other hand, for the mean serum osteopontin 
levels, there was no statistically significant interaction 
between PCOS status and obesity, F(1, 110) = .520, 
p = .473, partial eta squared = .005. There was a sta-
tistically significant main effect of obesity on mean 
osteopontin levels, F(1, 110) = 79.003, p < .001, partial 
eta squared = .418) The mean serum osteopontin lev-
els were markedly higher in obese PCOS and obese 
controls than in lean PCOS and controls (42.1, 44.1, 
15.5, and 12.8, respectively). However, there was no 
statistically significant difference in osteopontin levels 
between the PCOS and control groups, F(1,110) = .011, 
p = .918, partial eta squared < .001. A summary of the 
comparisons of control and PCOS cases after defining 
subgroups for obesity with respect to adiponectin, 
osteopontin, LH/FSH, FAI, SHBG, and DHEA-S are 
shown in Table 3.
Since only LH/FSH and adiponectin levels were 
found to be significantly different among lean control 
and lean PCOS patients, these parameters were inves-
tigated with respect to metabolic risk factors. Neither 
overall lean women nor the lean PCOS subgroup 












(n = 28) 
X ± SD
Obese Control 
(n = 29) 
X ± SD
Lean PCOS 
(n = 28) 
X ± SD
Obese PCOS 
(n = 29) 
X ± SD
LH/FSH ratio 0.8 ± 0.4 1.5 ± 0.9 < 0.001 0.9 ± 0.4 0.7 ± 0.7 1.5 ± 1.2 1.5 ± 1.5
FAI 0.7 ± 0.6 1.6 ± 1.9 0.001 0.8 ± 0.7 0.6 ± 0.4 1.2 ± 1.3 2.0 ± 2.3
SHBG 46.8 ± 16.9 45.8 ± 41.6 0.9 47.2 ± 16.6 46.5 ± 17.7 54.3 ± 52.4 37.6 ± 25.9
DHEA-S 220.5 ± 128.9 268.4 ± 122.7 0.04 256.8 ± 144.6 185.4 ± 102.3 277.8 ± 126.1 259.3 ± 221.7
Total cholesterol 173.4 ± 29.9 171.1 ± 36.5 0.7 159.8 ± 28.4 186.5 ± 25.5 159.6 ± 36.4 182.3 ± 33.7
LDL 100.6 ± 27.1 97.0 ± 29.8 0.5 88.1 ± 23.7 112.7 ± 24.8 85.1 ± 25.1 108.4 ± 29.8
HDL 55.2 ± 12.8 53.9 ± 13.7 0.6 57.8 ± 13.9 52.7 ± 11.3 58.7 ± 13.8 49.2 ± 12.2
Triglyceride 88.9 ± 42.4 101.7 ± 55.1 0.2 72.2 ± 30.4 105.1 ± 46.5 81.0 ± 28.7 121.5 ± 66.7
Fasting glucose 86.8 ± 11.2 84.7 ± 14.1 0.4 83.3 ± 8.4 90.0 ± 12.7 83.6 ± 19.3 85.6 ± 5.8
HOMA-IR 2.2 ± 1.2 2.7 ± 1.9 0.2 1.84 ± 0.98 2.6 ± 1.2 2.4 ± 2.2 2.8 ± 1.6
CRP 0.21 ± 0.25 0.28 ± 0.58 0.4 0.15 ± 0.19 0.27 ± 0.29 0.13 ± 0.15 0.43 ± 0.76
*p values were calculated between PCOS and control group; PCOS — polycystic ovarian syndrome, LH/FSH — luteinising hormone/follicle-stimulating hormone;  
FAI — free androgen index; SHBG — sex hormone binding globulin; DHEA-S — dehydroepiandrosterone sulphate; LDL — low-density lipoprotein; HDL — high-density 
lipoprotein; HOMA-IR — homeostatic model assessment of insulin resistance; CRP — C-reactive protein
Table 3. Comparison of control and polycystic ovarian syndrome (PCOS) cases with respect to adiponectin, osteopontin, 
luteinising hormone/follicle-stimulating hormone (LH/FSH), free androgen index (FAI), sex hormone binding globulin (SHBG), 
and dehydroepiandrosterone sulphate (DHEA-S) after defining subgroups for obesity 
Lean control vs. lean PCOS Obese control vs. obese PCOS
LH/FSH ratio Significant difference Significant difference
FAI NS Significant difference
SHBG NS NS
DHEA-S NS NS
Adiponectin Significant difference NS
Osteopontin NS NS
LH/FSH — luteinising hormone/follicle-stimulating hormone; FAI — free androgen index; SHBG — sex hormone binding globulin; DHEA-S — dehydroepiandrosterone 
sulphate; NS — non-significant
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showed significant correlation with the cholesterol 
panel, HOMA, or CRP levels. 
Discussion
In this study we compared 57 PCOS patients with 57 
age- and BMI-matched healthy controls with respect to 
their serum adiponectin and osteopontin values. Both 
groups were also divided into two subgroups: lean and 
obese. Antral follicle count and ovarian volume were 
found to be higher in the PCOS group, as expected. 
Similarly, LF/FSH ration, FAI, and DHEAS-S were found 
to be significantly higher in women with PCOS. Inter-
estingly the only baseline parameter that significantly 
differed between lean control and lean PCOS women 
appeared to be the LH/FSH ratio. Although mean adipo-
nectin and osteopontin levels were similar among cases 
and controls, a further two-way ANOVA comparison 
within lean and obese subgroups revealed additional 
information such as adiponectin being significantly 
different between lean control and lean PCOS women. 
The LH/FSH ratio and adiponectin levels were found 
to differ between lean counterparts, but they did not 
show any correlation with metabolic markers (choles-
terol panel, homeostatic model assessment [HOMA] or 
CRP levels), nor in overall lean women or in the lean 
PCOS subgroup. 
Metabolic dysfunction and chronic low-grade 
inflammation are the two main pathways involved 
because they are mainly induced by obesity and 
hyperandrogenism [23]. Daan et al. investigated the 
metabolic and inflammatory biomarker profiles in 
women with PCOS such as adipocytokines: interleukins 
(IL) — IL-1b, IL-6, IL-13, IL-17, IL-18, tumour necrosis 
factor alpha (TNF-a), adiponectin, adipsin, leptin, 
chemerin, resistin, retinol-binding protein 4 (RBP4), 
soluble CD26/dipeptidyl peptidase-IV (DPP-IV/sCD26), 
monocyte chemoattractant protein-1 (CCL2/MCP-1), 
growth factors — placental growth factor (PIGF), 
vascular endothelial growth factor (VEGF) and its 
soluble receptor (sVEGF-R1), and soluble cell adhesion 
molecules — soluble intercellular adhesion molecule 1 
(sICAM-1/sCD54) and soluble vascular cell adhesion 
molecule 1 (sVCAM-1/sCD106) [24]. Their analysis re-
vealed adiponectin as a potential discriminative marker 
for PCOS, and it was closely related with BMI. Adipo-
nectin is a cytokine showing anti-inflammatory features 
and inversely correlating with visceral adiposity and 
obesity [12]. Deregulations in its secretion have been 
speculated to be involved in PCOS pathogenesis [25]. 
Besides this, it may also be possible that PCOS indepen-
dently affects this adipokine expression. Other studies 
also demonstrated hypoadiponectinaemia in PCOS 
patients irrespective of obesity; however, we failed 
to establish a link between PCOS and serum levels of 
adiponectin in obese women [26, 27]. Similarly, Baldani 
et al. did not find a link between abdominal fat distri-
bution and serum adiponectin levels [18]. In contrast, 
Gandevani et al. reported that serum adiponectin levels 
were similar between obese and non-obese controls, but 
they found decreased adiponectin levels in obese PCOS 
women compared to their non-obese counterparts [28]. 
In this study, although no significant relation between 
PCOS and adiponectin levels was found, pairwise com-
parisons revealed that mean adiponectin levels were 
affected by there being PCOS only in the lean group. 
In other words, the significant interaction found in our 
study for PCOS and obesity showed that having PCOS 
did have a significant effect for the adiponectin levels in 
lean but not in obese women. This result is interesting 
because it indicates the possibility that adiponectin may 
have a much more associated role in the pathogenesis 
of PCOS in lean women than in obese women.
The main strength of this study was the comparison 
of relatively homogenous PCOS group with age and 
BMI-matched controls. Moreover, HOMA-IR and cho-
lesterol levels between these groups were also compa-
rable. The main reason for this similarity may be the fact 
that both groups were also stratified for obese and lean 
counterparts. However, this condition diminishes the 
generalisability of these results to a larger population 
in which this kind of matching is not present. 
Osteopontin is another cytokine with pro-inflam-
matory effects that is different from adiponectin. On 
the other hand, it is similarly related with adipose tis-
sue, and it was previously shown in an animal obesity 
model that its expression increases in adipose tissue 
[29]. It was also shown that osteopontin is related with 
insulin resistance and adipose tissue inflammation 
[30]. A recent study by Saklamaz et al. documented 
that osteopontin levels were increased in PCOS [19]. 
They also documented that serum osteopontin levels 
in overweight/obese women were higher than in lean 
women regardless of PCOS. In this study, we similarly 
found no interaction with PCOS status and obesity 
for osteopontin levels. However, we did not find any 
relationship between PCOS status and osteopontin 
levels in main effect comparison, but we observed 
a very distinct increment in the overall obese group. 
Therefore, one explanation for the insignificant rela-
tion found in our study may be related with this high 
correlation of osteopontin with obesity. However, 
continuation of this insignificancy in the lean counter-
parts hampers the logic for this comment. Therefore, 
one can speculate that osteopontin is not involved in 
PCOS pathogenesis as much as adiponectin. Another 
speculative explanation would be one or more con-
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a finding. Further studies with larger sample sizes 
and homogeneous subgroups are needed to draw de-
finitive conclusions. It should be noted that the PCOS 
and control groups in this study had quite similar IR 
and therefore these results could not be generalised 
to other populations. Another limitation in this study 
may arise from age differences between the PCOS and 
control groups. Although matching for age resulted in 
no significance of age difference, it should be kept in 
mind that serum adiponectin levels may be affected by 
the slightly older age in the control group.
In this study, only the LH/FSH ratio and adiponectin 
levels were found to significantly differ between lean 
controls and lean PCOS women. We were, however, 
unable to document a significant correlation of LH/FSH 
ratio and adiponectin levels with cholesterol panel, 
HOMA, or CRP levels. In our results, the correlation 
between adiponectin and other metabolic risk factors 
was limited. However, the distinct result we found in 
the lean subgroup may indicate an important clinical 
association in the lean PCOS subgroup. One sensational 
speculation may also be derived from this lack of cor-
relation; adiponectin levels in lean women may stand 
as a long-term metabolic risk factor, being much more 
sensitive than lipid profile or HOMA calculation. This 
possibility should further be investigated prospectively 
in a larger subgroup.
Conclusion
Serum adiponectin levels were significantly lower in 
lean PCOS women compared to lean controls; however, 
PCOS status did not affect adiponectin levels in obese 
women. On the other hand, mean adiponectin and 
osteopontin levels were similar between PCOS cases 
and controls overall. There is a need for prospective 
research investigating the clinical value of adiponectin 
as a long-term metabolic risk factor in lean cases.
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